RadNet, Inc. (RDNT) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Cash Conversion ⢠Margin Compression ⢠Rising Leverage Radiant generates solid operating and free cash flow, but shrinking margins, an interest burden that exceeds EBIT, rising leverage, and a rich valuation make the equity case fragile.
Price Behavior
Key Price Behavior Insights: ⢠Downtrend intact ⢠Support holding ⢠Resistance overhead Support Level: $51.9â$52.8 Resistance Level: $55.3â$55.5 Over the last month, RDNT has stayed in a short-term downtrend, but the rebound from $51.87 shows buyers are defending support as the stock tries to reclaim $55.3â$55.5 resistance.
Sentiment & News
Key News Insights: ⢠Record Q1 ⢠Raised Guidance ⢠New Financing RadNet reported record Q1 revenue and EBITDA and raised 2026 guidance despite an EPS miss and weather disruption, while analyst upgrades, active trading, and new financing plans reinforce its growth momentum.
AI Summary
RDNT should now be viewed as a cash-generating growth story under balance-sheet pressure, where the real investment question is whether revenue gains and AI/joint-venture spending can lift margins fast enough to offset rising debt, interest expense, and shrinking financial flexibility.
Description
RadNet, Inc. operates a network of outpatient diagnostic imaging centers across multiple U.S. states, providing services such as MRI, CT, PET, mammography and other multimodality imaging procedures. The company also supplies imaging IT systems, including picture archiving and communication solutions, and has developed software tools to support radiologist interpretation in areas including mammography, lung and prostate cancer. Founded in 1981 and headquartered in Los Angeles, RadNet owned and managed 347 centers as of December 31, 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 8 | Sep 15 | RDNT | RadNet, Inc. | RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks. | Closed | +4.2% |